Recurrent mutations in the JAK–STAT, NF-κB, and B-cell receptor (BCR) pathways, including CD79B, MYD88, and CDKN2A deletions, have been identified as the defining characteristics of primary central nervous system lymphomas (15–17). Here, MYD88 is linked to primary central nervous system lymphoma.